MFA011 / MediMabBio - LARVOL DELTA

Two is better than one: First in class anti-TIGIT IL-15 fusion antibody for enhanced tumor killing (AACR 2025) - "Dual targeting of TIGIT and IL-15 signalling through MFA011 effectively enhances anti-tumor immune responses while limiting the off-target effects of IL-15 signalling. Our combined in vitro and in vivo data provides strong evidence to pursue MFA011 to IND filing and to commence phase I clinical trials."

Oncology • Solid Tumor • CD8 • IFNG • IL15 • PVR • TIGIT

Development of a novel anti-TIGIT IL-15 fusion antibody for enhanced anti-tumour therapy (EACR 2024) - "Although IL-15 has strong potential for immunotoxicity, in vitro and in vivo assays have demonstrated minimal toxicity and effective targeting of MFA011. In accordance with in vitro data, MFA011 also demonstrated enhanced immune responses in vivo as demonstrated by a reduction in tumour volume in CT26-bearing mice.Conclusion Dual targeting of TIGIT and IL-15 signalling through MFA011 effectively enhances anti-tumour immune responses while limiting the off-target effects of IL-15 signalling."

Oncology • CD8 • IFNG • IL15 • IL2 • PVR • TIGIT